Department of Ophthalmology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga, 520-2192, Japan.
J-CREST (Japan Clinical Retinal Study Team) Study Group, Tokyo, Japan.
Jpn J Ophthalmol. 2023 Mar;67(2):149-155. doi: 10.1007/s10384-023-00981-0. Epub 2023 Mar 7.
To investigate age-specific prevalence of disease subtypes and baseline best-corrected visual acuity (BCVA) in Japanese patients with treatment-naïve neovascular age-related macular degeneration (nAMD).
Retrospective multicenter case series.
We reviewed the records of patients with treatment-naïve nAMD who underwent initial treatment in 14 institutions in Japan sometime during the period from 2006 to 2015. In patients in whom both eyes were treated, only the eye treated first was included for analysis. The patients were stratified by age for the analysis.
In total, 3096 eyes were included. The overall prevalence of subtypes was as follows: typical AMD, 52.6%; polypoidal choroidal vasculopathy (PCV), 42.8%; retinal angiomatous proliferation (RAP), 4.6%. The number of eyes in each age group was as follows: younger than 60 years, 199; 60s, 747; 70s, 1308; 80s, 784; 90 years or older, 58. The prevalence of typical AMD in each age group was 51.8%, 48.1%, 52.1%, 57.7%, and 55.2%, respectively. The prevalence of PCV was 46.7%, 49.1%, 44.7%, 34.4%, and 19.0%, respectively. The prevalence of RAP was 1.5%, 2.8%, 3.2%, 7.9%, and 25.9%, respectively. The prevalence of PCV decreased with age, whilst that of RAP increased. The prevalence of RAP was higher than that of PCV in patients aged 90 years or older. The mean baseline BCVA (logMAR) was 0.53. In each age group, the mean baseline BCVA was 0.35, 0.45, 0.54, 0.62, and 0.88, respectively. The mean logMAR BCVA at baseline significantly worsened with age (P < 0.001).
The prevalence of nAMD subtypes differed according to age in Japanese patients. The baseline BCVA worsened with age.
研究日本未经治疗的新生血管性年龄相关性黄斑变性（nAMD）患者的疾病亚型的特定年龄患病率和基线最佳矫正视力（BCVA）。
回顾性多中心病例系列研究。
我们回顾了 2006 年至 2015 年间在日本 14 家机构接受初次治疗的未经治疗的 nAMD 患者的记录。对于双眼均接受治疗的患者，仅对初次治疗的眼进行分析。患者按年龄分层进行分析。
共纳入 3096 只眼。各亚型的总体患病率如下：典型 AMD，52.6%；息肉状脉络膜血管病变（PCV），42.8%；视网膜血管性增殖（RAP），4.6%。每个年龄组的眼数如下：60 岁以下，199 只；60 多岁，747 只；70 多岁，1308 只；80 多岁，784 只；90 岁或以上，58 只。每个年龄组的典型 AMD 患病率分别为 51.8%、48.1%、52.1%、57.7%和 55.2%。PCV 的患病率分别为 46.7%、49.1%、44.7%、34.4%和 19.0%。RAP 的患病率分别为 1.5%、2.8%、3.2%、7.9%和 25.9%。随着年龄的增长，PCV 的患病率降低，而 RAP 的患病率增加。90 岁或以上患者的 RAP 患病率高于 PCV。基线 BCVA（logMAR）的平均值为 0.53。在每个年龄组中，基线 BCVA 的平均值分别为 0.35、0.45、0.54、0.62 和 0.88。基线 logMAR BCVA 随年龄显著恶化（P < 0.001）。
日本 nAMD 患者的疾病亚型患病率因年龄而异。基线 BCVA 随年龄增长而恶化。
